Monte Rosa Q3 net loss $34.9M; cash runway into H1 2026 after Roche deal and $25M offering

Monte Rosa Therapeutics, Inc.

Net loss $34.9M vs $27.3M in Q3 2022; R&D expenses $28.3M, G&A $8.7M.
Cash & securities $183M at Sep 30, 2023; excludes $50M Roche upfront and $25M direct offering received after quarter.
Announced interim Phase 1/2 data for MRT-2359 showing tumor reductions in MYC-driven solid tumors; RP2 dose expected Q2 2024.
Roche collaboration to discover MGDs; $50M upfront, potential milestones >$2B plus royalties.
Discontinued sickle cell program; MRT-6160 IND submission planned 1H 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Monte Rosa Therapeutics, Inc. reported the quarter ended September 30, 2023 results: net income Net loss for the third quarter of 2023 was $34.9 million.

Period: the quarter ended September 30, 2023
Net income: Net loss for the third quarter of 2023 was $34.9 million
Result: reported results

Exact text from the filing

Net loss for the third quarter of 2023 was $34.9 million, compared to $27.3 million for the third quarter of 2022.

View on SEC.gov

Browse all earnings releases →

Monte Rosa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-061530

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.